Concentric Analgesics

Executive Summary

Concentric Analgesics is a private biotechnology company headquartered in Los Altos, CA, dedicated to developing novel non-opioid therapeutics for acute postsurgical and chronic osteoarthritis pain. The company was founded in 2016 and is leveraging its proprietary platform to create a pipeline of small-molecule analgesics that aim to provide effective pain relief without the risk of addiction or opioid-related side effects. Concentric's lead candidate targets a novel mechanism in the pain pathway and has shown promising preclinical and early clinical data. By focusing on non-opioid alternatives, the company addresses a critical unmet need amid the ongoing opioid crisis, potentially offering safer options for managing pain in surgical and osteoarthritis patients. The firm is currently advancing its lead asset through clinical development and is actively seeking strategic partnerships to accelerate its programs. Concentric Analgesics is well-positioned within the competitive landscape of pain management, where there is a strong demand for non-addictive and effective therapies. The company's approach could capture significant market share if clinical trials demonstrate superior efficacy or safety compared to existing treatments. Key upcoming milestones include results from a Phase 2 trial in acute postsurgical pain and progression of its osteoarthritis program. The company's private status limits public visibility, but its focus on a high-need area and a strong scientific foundation suggest potential for substantial value creation upon successful clinical readouts or partnering events. Investors should monitor regulatory interactions and announcement of pivotal trial designs as near-term value drivers.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 top-line results for lead candidate in acute postsurgical pain35% success
• Q2 2027Initiation of Phase 3 trial for osteoarthritis pain40% success
• Q4 2026Strategic partnership or licensing deal for ex-US rights50% success